

PRODUCT

PSMA-targeting ligand.

INDICATION

Prostate cancer.

VALUE PROPOSITION

- Next-gen PSMA targeting
- Superior specificity and biodistribution.
- Increased therapeutic efficacy and dosing with minimized side effects.

DEVELOPMENT STAGE

IND-enabling studies commencing with validated GMP material.

INTELLECTUAL PROPERTY

Issued Patents:

- [US 9,713,649](#)
- [US 10,918,741](#)

Pending Applications:

- [US 17/770,382](#)
- [CA 3,155,519](#)
- [EP 4041213A1](#)

PUBLICATIONS

- Fuchs AV, et al. Biomacromolecules. 2015 Oct 12;16(10):3235-47. [PMID: 26335533](#).
- Huang SS, et al. Prostate. 2014 May;74(7):702-13 [PMID: 24615708](#).
- Wang X, et al. Mol Cancer Ther. 2014 Nov;13(11): 2595-606. [PMID: 25239933](#)

CONTACT INFORMATION

Joe Barone
Director, Business Development
baronej2@ccf.org
(631) 278-5858

Next-generation PSMA Targeting Theranostic Platform


OPPORTUNITY

- Approved products Locametz, Pylarify, and Pluvicto have demonstrated effectiveness for diagnosis and treatment of prostate cancer, respectively, through targeting prostate specific membrane antigen (PSMA).
- PSMA-targeting radionuclide therapies are associated with side-effects caused by off-target radiation, including salivary gland impairment causing severe, chronic dry mouth (xerostomia).

SOLUTION

- Steve Huang, MD and colleagues in the Cleveland Clinic Department of Nuclear Medicine have developed next-generation novel peptidic tracers that target PSMA.
- These tracer molecules rapidly and specifically accumulate in PSMA+ prostate tumors and metastases of PSMA+ tumor origin and are almost entirely excluded from salivary gland tissue.
- Broad utility of this tracer has been demonstrated as a means for tumor detection and therapeutic targeting.
- Novel tracer design is expected to improve efficacy while minimizing radiological side effects.
- PSMA, LLC, a wholly owned Cleveland Clinic product development company, has an exclusive option to the technology and is advancing the product to IND-enablement.
- Actively seeking partners for collaboration and commercialization.

MicroPET Pilot Study



**Recognized standard with biodistribution representative of leading PSMA tracer technologies.*